Free Trial

Assetmark Inc. Buys 1,004 Shares of CME Group Inc. (NASDAQ:CME)

CME Group logo with Finance background

Assetmark Inc. boosted its stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) by 4.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 25,081 shares of the financial services provider's stock after buying an additional 1,004 shares during the period. Assetmark Inc.'s holdings in CME Group were worth $6,654,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Wayfinding Financial LLC bought a new position in shares of CME Group during the 1st quarter worth $25,000. Cornerstone Planning Group LLC lifted its stake in CME Group by 122.2% in the first quarter. Cornerstone Planning Group LLC now owns 100 shares of the financial services provider's stock worth $26,000 after acquiring an additional 55 shares during the period. New Age Alpha Advisors LLC grew its holdings in CME Group by 50.0% during the 4th quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock worth $30,000 after acquiring an additional 43 shares in the last quarter. Golden State Wealth Management LLC increased its position in CME Group by 612.5% during the 1st quarter. Golden State Wealth Management LLC now owns 114 shares of the financial services provider's stock valued at $30,000 after purchasing an additional 98 shares during the period. Finally, Alpine Bank Wealth Management bought a new stake in shares of CME Group in the 1st quarter valued at about $32,000. 87.75% of the stock is currently owned by institutional investors.

CME Group Stock Up 0.9%

Shares of CME Group stock opened at $279.55 on Monday. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.12. CME Group Inc. has a 52-week low of $193.25 and a 52-week high of $290.79. The company has a market capitalization of $100.74 billion, a P/E ratio of 27.06, a P/E/G ratio of 4.96 and a beta of 0.44. The company has a 50 day moving average of $276.44 and a 200 day moving average of $262.72.

CME Group (NASDAQ:CME - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The financial services provider reported $2.96 earnings per share for the quarter, topping the consensus estimate of $2.91 by $0.05. CME Group had a return on equity of 14.60% and a net margin of 58.48%. The business had revenue of $1.69 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the company earned $2.56 EPS. The business's quarterly revenue was up 10.4% on a year-over-year basis. As a group, research analysts forecast that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were given a dividend of $1.25 per share. The ex-dividend date was Monday, June 9th. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.79%. CME Group's dividend payout ratio (DPR) is presently 48.40%.

Insider Buying and Selling at CME Group

In other CME Group news, Director Dennis Suskind sold 1,000 shares of the firm's stock in a transaction on Tuesday, April 29th. The shares were sold at an average price of $271.28, for a total transaction of $271,280.00. Following the transaction, the director directly owned 2,915 shares of the company's stock, valued at approximately $790,781.20. This trade represents a 25.54% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Charles P. Carey sold 3,000 shares of the firm's stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $272.56, for a total value of $817,680.00. Following the transaction, the director directly owned 5,400 shares in the company, valued at approximately $1,471,824. This represents a 35.71% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 11,400 shares of company stock valued at $3,152,410. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several brokerages recently issued reports on CME. Keefe, Bruyette & Woods lifted their price objective on shares of CME Group from $265.00 to $273.00 and gave the company a "market perform" rating in a report on Thursday, April 24th. Morgan Stanley lifted their price target on CME Group from $301.00 to $304.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Citigroup boosted their price target on CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research report on Thursday, July 3rd. Barclays dropped their price objective on CME Group from $299.00 to $298.00 and set an "equal weight" rating on the stock in a research report on Thursday. Finally, Royal Bank Of Canada reiterated a "sector perform" rating and issued a $269.00 target price on shares of CME Group in a research note on Thursday, April 3rd. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, CME Group presently has a consensus rating of "Hold" and a consensus target price of $261.93.

Get Our Latest Stock Report on CME Group

CME Group Profile

(Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Featured Articles

Want to see what other hedge funds are holding CME? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CME Group Inc. (NASDAQ:CME - Free Report).

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in CME Group Right Now?

Before you consider CME Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.

While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines